Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report) shares were down 2.7% during trading on Friday . The stock traded as low as $0.33 and last traded at $0.36. Approximately 2,808 shares were traded during trading, a decline of 99% from the average daily volume of 281,870 shares. The stock had previously closed at $0.37.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a “neutral” rating on shares of Panbela Therapeutics in a research report on Thursday, August 15th.
Check Out Our Latest Stock Report on Panbela Therapeutics
Panbela Therapeutics Trading Down 2.7 %
Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($1.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.07) by $0.60. Sell-side analysts forecast that Panbela Therapeutics, Inc. will post -6.76 EPS for the current fiscal year.
About Panbela Therapeutics
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Further Reading
- Five stocks we like better than Panbela Therapeutics
- How to Use the MarketBeat Excel Dividend Calculator
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- The 3 Best Blue-Chip Stocks to Buy Now
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- Are Penny Stocks a Good Fit for Your Portfolio?
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.